Toronto, Ontario-(June 12, 2023) - Psyched Wellness Ltd. (CSE: PSYC) (OTCQB: PSYCF) (FSE: 5U9) (the "Company" or "Psyched Wellness"), a life sciences company focused on the production and distribution of health and wellness products derived from the Amanita Muscaria mushroom, is pleased to announce that it has closed the initial tranche ("Initial Tranche") of its previously announced non-brokered private placement (the "Offering"), the details of which are described in the Company's press release dated May 30, 2023 (the "May 30 Release"). Pursuant to Initial Tranche, the Company has issued 9,585,000 units of the Company ("Units") at a price of C$0.07 per Unit for gross proceeds of US$500,000, approximately C$670,950, based on an exchange rate of US$1.00 = C$1.3419 as at June 6, 2023, as published on the website of the Bank of Canada.
Capitalized terms not otherwise defined herein have the meanings attributed to them in the May 30 Release.
Each Unit consists of one (1) Common Share and one (1) Warrant. Each Warrant entitles the holder thereof to acquire one (1) Additional Share at a price of C$0.10 per Additional Share at any time for a period of sixty (60) months from the date of issuance, exercisable on a cashless basis, subject to acceleration and compliance with the policies of the CSE, as further outlined in the May 30 Release.
All securities issued under the Initial Tranche are subject to: (i) a four (4) month and one (1) day hold period from the date of issuance and (ii) applicable legends as required pursuant to the U.S. Securities Act. The Company intends to use the net proceeds from the Offering for working capital and general corporate purposes.
As an additional condition to the closing of the Initial Tranche, the current Board members and officers of the Company entered into support agreements to vote their Common Shares at the Meeting in favor of approving a subsequent tranche of the Offering for the purchase of US$7,000,000 worth of Units ("Tranche 2") and the issuance of the Units representing Tranche 2 (the "Transaction Resolution").
Investor Rights Agreement
In connection with closing the Initial Tranche, the Company, Gotham Green Fund III, L.P. and Gotham Green Fund III (Q), L.P. (together, "Gotham") entered into an investor rights agreement dated June 12, 2023 (the "Investor Rights Agreement") which replaces the Term Sheet, and which provides, among other things, that:
provided that no more than three (3) Board members, at any time, will be employees or partners of the Investors (as defined herein) and/or their affiliates.
In addition, pursuant to the terms of the Investor Rights Agreement:
(i) the Company granted exclusivity to Gotham for a period of ninety (90) days following the closing of the Initial Tranche, during which time the Company and its directors, officers, and representatives are prohibited from directly or indirectly discussing, negotiating, or entering into any agreement or arrangement with respect to any potential financing transaction, sale transaction or other strategic transaction with any third party; and
(ii) within five (5) business days following the satisfaction and/or waiver of the Tranche 2 Closing Conditions (as defined herein), including prior approval by Shareholders pursuant to the policies of the CSE, the Company anticipates closing Tranche 2 led by Gotham and anticipated to include affiliates and/or co-investors (together, the "Investors"). Closing of Tranche 2 is conditional upon the completion of the following (the "Tranche 2 Closing Conditions"):
Upon closing of Tranche 2, the Company has agreed to reimburse the Investors for reasonable and documented out-of-pocket expenses incurred in connection with the Offering in the amount of up to C$15,000.
The Investor Rights Agreement will terminate on the earliest of: (i) the written agreement of Gotham and the Company; (ii) the date on which Gotham ceases to hold any securities of the Company; (iii) if Gotham provides a notice to the Company that closing of Tranche 2 will not occur; and (iv) by the Company by written notice to Gotham, if Gotham has not delivered a Tranche 2 Closing Notice to the Company by the date which is ninety (90) days from the date of the Investor Rights Agreement, or such other date as the parties may agree in writing.
The 9,585,000 Units issued in the Initial Tranche consist of 9,585,000 Common Shares and 9,585,000 Warrants, representing 6.59% of the current issued and outstanding Common Shares on a non-diluted basis and 12.37% on a partially diluted basis.
Gotham has no obligation to acquire any Units under Tranche 2. The Units issuable in connection with Tranche 2 shall be issued to the Investors within five business days following the satisfaction and/or waiver of the Tranche 2 Closing Conditions, subject to the terms and conditions of the Investor Rights Agreement. Accordingly, as a result of the Offering, Gotham may be considered to have beneficial ownership over the Units issuable in connection with Tranche 2 in addition to the Units issued in the Initial Tranche.
If the Company is successful in closing Tranche 2, and assuming an exchange rate of US$1.00 = C$1.3419 as at June 6, 2023, as published on the website of the Bank of Canada, the Investors are expected to have beneficial ownership of up to 287,550,000 Common Shares (comprised of up to 143,775,000 issued Common Shares and up to a further 143,775,000 Common Shares issuable upon exercise of the Warrants), which represents 51.43% of the current issued and outstanding Common Shares on a non-diluted basis and 67.92% on a partially-diluted basis as of the date hereof.
The Company will make the Investor Rights Agreement available on its SEDAR profile available at www.sedar.com.
-30-
Neither the Canadian Securities Exchange nor its Regulation Services Provider have reviewed or accept responsibility for the adequacy or accuracy of this release.
About Psyched Wellness Ltd.:
Psyched Wellness Ltd. is a Canadian-based health supplements company dedicated to the distribution of mushroom-derived products and associated consumer packaged goods. The Company’s objective is to create premium mushroom-derived products that have the potential to become a leading North American brand in the emerging functional food category. The Company is in the process of developing a line of Amanita muscaria-derived water-based extracts, teas and capsules designed to help with three health objectives: promote stress relief, relaxation and assist with restful sleeping.
Cautionary Statement Regarding Forward Looking Information
This press release contains “forward-looking information” within the meaning of applicable Canadian securities legislation. These statements relate to future events or future performance. The use of any of the words “could”, “intend”, “expect”, “believe”, “will”, “projected”, “estimated” and similar expressions and statements relating to matters that are not historical facts are intended to identify forward-looking information and are based on the Company’s current belief or assumptions as to the outcome and timing of such future events. The forward-looking information and forward- looking statements contained herein include, but are not limited to, statements regarding: the ability of the Company to develop Amanita Muscaria-derived products; the safety of Amanita Muscaria consumption and the safety and purity of any extracts thereof; and (ii) the uses and potential benefits of Amanita Muscaria.
Forward-looking information in this news release are based on certain assumptions and expected future events, namely: the Company’s ability to continue as a going concern; the Company’s ability to continue to develop its mushroom-derived products and associated consumer packaged goods; continued approval of the Company’s activities by the relevant governmental and/or regulatory authorities; and the continued growth of the Company.
These statements involve known and unknown risks, uncertainties and other factors, which may cause actual results, performance or achievements to differ materially from those expressed or implied by such statements, including but not limited to: the potential inability of the Company to continue as a going concern; risks associated with potential governmental and/or regulatory action with respect to the Company’s operations; competition within the psychedelics market; risks with respect to the safety of Amanita Muscaria consumption and the safety and purity of any extracts thereof; and the risk that there is no potential benefit of Amanita Muscaria consumption.
Readers are cautioned that the foregoing list is not exhaustive. Readers are further cautioned not to place undue reliance on forward-looking statements, as there can be no assurance that the plans, intentions or expectations upon which they are placed will occur. Such information, although considered reasonable by management at the time of preparation, may prove to be incorrect and actual results may differ materially from those anticipated.
Forward-looking statements contained in this news release are expressly qualified by this cautionary statement and reflect the Company’s expectations as of the date hereof and are subject to change thereafter. The Company undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, estimates or opinions, future events or results or otherwise or to explain any material difference between subsequent actual events and such forward-looking information, except as required by applicable law.
For further information, please contact:
Jeffrey Stevens
Chief Executive Officer
Psyched Wellness Ltd.
t: (647) 400-8494
e: jstevens@psyched-wellness.com
Website: http://www.psyched-wellness.com
Investor Contacts:
Tim Regan/Sophia Bashford
KCSA Strategic Communications
t: (978) 505-2478
e: PsychedWellness@kcsa.com